EUVIMED · CrossrefJournal
Lung Cancer: Targets and Therapy
ISSN 1179-2728 · Informa UK Limited
Latest articles
Expert Consensus Recommendations on NSCLC Management: Evidence-Based Strategies for Early Resectable and Locally Advanced Disease from Asia
Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study
Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung Cancer
Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?
Unilateral Scleral Icterus as a Rare Presentation of Choroidal Metastasis in Transdifferentiated EGFR-Mutant Lung Cancer: A Case Report and Review of the Literature
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report
Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
Comprehensive review of fetal adenocarcinoma of the lung
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects
Oligometastatic non-small-cell lung cancer: current treatment strategies
Modern management of malignant pleural mesothelioma
Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
EUVIMED